http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Changhoon Yoo (검색결과 41 건)
- 무료
- 기관 내 무료
- 유료
-
-
-
-
-
-
Changhoon Yoo,Sung Bae Kim,Jin Hee Ahn,Kyung Hae Jung,Yongchel Ahn,Gyungyub Gong,Hak-Hee Kim,Hee-Jung Kim,손병호,Sei-Hyun Ahn 한국유방암학회 2011 Journal of breast cancer Vol.14 No.2
Purpose: Fulvestrant, a potent estrogen receptor (ER) antagonist with a novel mechanism of action, has shown efficacy in pretreated patients with advanced breast cancer. We assessed the efficacy and tolerability of fulvestrant in Korean postmenopausal women. Methods: Of the 25 candidates identified at Asan Medical Center, Seoul, Korea, six were deemed ineligible due to inadequate baseline and follow-up imaging. The 19 patients included in this retrospective analysis received the approved dose of fulvestrant (250 mg intramuscular injection, once per month) as second- (n=8), third- (n=7), or fourth-line (n=4) endocrine therapy. Results: At a median follow-up of 7.4 months (range, 1.2-34.8 months), the 19 patients received a median of four cycles (range, 1-34 cycles) of fulvestrant. Median time to progression was 5.5 months (95% confidence interval [CI], 0.4-10.7 months), and median overall survival was 17.9 months (95% CI, 2.7-33.1 months). Among 17 evaluable patients, one (5.3%) achieved a partial response, 10 (52.6%) showed stable disease, and six (31.6%) showed progressive disease. The clinical benefit rate was 26.3%. Four patients (21.1%) reported adverse events, but all were grade 1 or 2. Conclusion: Fulvestrant was effective and well tolerated in patients with advanced breast cancer who had been previously treated with several lines of endocrine and chemotherapeutic agents.
-
( Changhoon Yoo ),( Dok Hyun Yoon ),( Shin Kim ),( Chan Sik Park ),( Jooryung Huh ),( Sang Wook Lee ),( Jung Sun Park ),( Cheolwon Suh ) 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: Although serum Beta-2 microglobulin (B2M) has been suggested as a prognostic factor for several hematologic malignancies, this was rarely investigated in marginal zone lymphoma (NZL). Materials: Between January, 2000, and May, 2013, a total of 270 patients with non-gastric (NG)-MZL were identified from database of Asan Medical Center, Seoul, Korea. Among them, pretreatment baseline serum B2M was available in 204 patients. Progression-free survival (PFS) and overall survival (OS) were compared according to the level of B2M with cut-off value of 2.5 mg/L. Results: Median age of study population was 51 year-old (range, 16-81) and 85 (42%) patients were male. Thirty (15%) patients had nodal MZL and 174 (85%) had extranodal MALToma. B2M =2.5 mg/L was related with more adverse clinical features, such as poor performance status, =2 extranodal sites, advanced stage (III-IV), anemia, elevated LDH, bone marrow invasion, and higher IPI risk group. In univariate analysis, serum B2M (<2.5 mg/L vs =2.5 mg/L) was significantly associated with PFS (p<0.001) and OS (p<0.001). In multivariate analysis including B2M and International Prognostic Index (IPI), serum B2M =2.5 mg/L was an independent adverse prognostic factor in terms of PFS (hazard ratio [HR]=3.7, 95% CI, 1.5-9.1; p=0.005) and OS (HR=7.5, 95% CI, 1.7-32.7; p=0.008). In analysis including Korean MZL Prognostic Index (MZLPI: nodal MZL, ECOG performance status =2 and advanced stage), B2MG =2.5 mg/L was also significant for PFS (HR=3.5, 95% CI, 1.5-7.7; p=0.003) and OS (HR=7.3, 95% CI 1.9- 28.2; p=0.004). Conclusion: In patients with NG-MZL, baseline serum B2M is a powerful prognostic factor for PFS and OS, independent of validated prognostic indexes, such as MZLPI and IPI.
-
-
-
Harvesting Performance of the Prototype Small Combine for Buckwheat and Adlay
Yoo, Soonam,Lee, Changhoon,Lee, Beom Seob,Yun, Young Tae Korean Society for Agricultural Machinery 2018 바이오시스템공학 Vol.43 No.4
Purpose: The aim of this study was to investigate the harvesting performance of a prototype small combine for buckwheat and adlay. Methods: The prototype small combine was designed and constructed. Its ratio of grain loss, ratio of output components in the grain outlet, and field capacity for harvesting buckwheat and adlay were analyzed through field tests. Results: The prototype small combine required a working width of about 0.6 to 0.7 m to harvest buckwheat. The maximum travel speed was about 0.36 m/. The total ratio of grain loss was about 21.6%, which consisted of 8.8% at the header and 12.8% at the dust outlet. The grain and the material other than grain (MOG) ratios at the grain outlet were 94.1% and 5.9% respectively. In the case of adlay harvest, the maximum working width was about 1.2 m, that is, two rows. The range of maximum travel speed was about 0.45 to 0.46 m/s. When adlay was harvested in one row, the total ratio of grain loss ranged from 36.3 to 42.8% according to the cutting height. The cutting height of 30 cm resulted in a higher total ratio of grain loss than 60 cm and 90 cm. When the cutting height was 60 cm, there was no significant change in the total ratio of grain loss according to the number of working rows and the stage of the primary transmission shift. The total ratio of grain loss ranged from 35.2 to 37.7%. The grain and the MOG ratios at the grain outlet ranged from 93.1 to 95.8% and from 4.2 to 6.9%, respectively. No significant difference was observed in relation to cutting height, number of working rows, and the stage of the primary transmission shift. Conclusions: The prototype small combine for harvesting miscellaneous cereal crops showed good potential for the efficient harvesting of buckwheat and adlay. However, to improve the harvesting performance, there seems to be a need to develop new crop varieties suitable for machine-based harvesting and improve the transmissions, reels, separation/cleaning systems.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
